Celsense
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Spinout | ||
N/A | $140k | Convertible | |
$150k | Seed | ||
N/A | $720k | Series A | |
N/A | $760k | Seed | |
N/A | $680k | Seed | |
N/A | $240k | Grant | |
N/A | Grant | ||
N/A | $270k | Early VC | |
N/A | $353k | - | |
N/A | $130k | Late VC | |
N/A | $500k | Late VC | |
$3.1m | Grant | ||
Total Funding | €6.4m |
Related Content
Recent News about Celsense
EditCelsense, Inc. specializes in developing advanced imaging agents that enable real-time MRI detection of inflammation and cellular therapeutics. Operating in the biomedical imaging market, Celsense serves healthcare providers, research institutions, and pharmaceutical companies. The company's core products, Cell Sense and V Sense, utilize perfluorocarbon emulsions to visualize and measure biological processes at the cellular level using fluorine magnetic resonance imaging (19F MRI) techniques. Celsense generates revenue through the sale of these imaging agents and related services, positioning itself as a leader in cellular imaging for human health.
Keywords: MRI detection, cellular therapeutics, inflammation imaging, perfluorocarbon emulsions, 19F MRI, biomedical imaging, healthcare providers, research institutions, pharmaceutical companies, cellular imaging.